Utama › Polsitemia Vera › North Carolina
Kajian klinikal Polsitemia Vera di North Carolina
6 kajian untuk Polsitemia Vera sedang mencari peserta di lokasi di North Carolina.
Bandar di North Carolina
Teks kajian rasmi (Bahasa Inggeris)
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Atrium Health Cabarrus/LCI-Concord, Concord
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT06661915Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- University of North Carolina At Chapel Hill, Chapel Hill
- Levine Cancer Institute, Charlotte
- Duke University Medical Center, Department of Hematologic Malignancies and Cellular Therapy, Durham
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Jul 2026 · NCT07441694Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- dan 4 lagi
Mengambil pesertaKajian pemerhatian
Umur 65 ke atas · Semua jantina · Dikemas kini 29 Jun 2026 · NCT01137825A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
- DUHS Duke Blood Cancer Center ( Site 6005), Durham
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Apr 2026 · NCT06351631Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
- University of North Carolina at Chapel Hill, Chapel Hill
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Mac 2026 · NCT06093672Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 120 · Semua jantina · Dikemas kini 27 Okt 2025 · NCT01137643Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.